Evidence map›Paper›PMID 41450928›Full record

SynthesisFrontiers in oncology2025

Diagnostic value of

Jiayue Sun, Yilin Hou, Chengfei Sun, Di Wu, Yunfei Zhang

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiayue Sun *Department of Ultrasound, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Yilin Hou *Department of Ultrasound, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Chengfei SunDepartment of Ultrasound, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun, Liaoning, China.
Di WuDepartment of Ultrasound, Liaoning Cancer Institute and Hospital, Shenyang, Liaoning, China.
Yunfei ZhangDepartment of Ultrasound, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Thyroid nodules classified as Bethesda category IV cannot be diagnosed with fine-needle aspiration. Methods: A literature search of the PubMed, Embase, Cochrane Library, Web of Science and OVID databases was conducted. In all of the included studies, the diagnostic accuracy of Results: A total of 10 studies were included after screening, comprising 913 cases of Bethesda Category IV nodules. Among them, there were 246 malignant lesions and 667 benign lesions. The pooled sensitivity of Conclusion: Systematic Review Registration: https://www.crd.york.ac.uk/prospero, identifier CRD42024608197.

Indexed as

Bethesda category IVcancermeta analysisRAS mutationthyroid nodules

Identifiers

PMID41450928
PMCPMC12727629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.